Abstract
Epidemiologic studies associate elevated maternal serum levels of α-fetoprotein (AFP) with reduced breast cancer risk for parous women. Laboratory studies demonstrate direct anti-breast cancer activity of AFP. Here, we review the development of a small cyclic peptide that is an active site analog of AFP, referred to as AFPep, which is composed exclusively of amino acids, is orally active, has no discernable toxicity, and is effective for the treatment and prevention of breast cancer in animal models.
©2014 American Association for Cancer Research.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / epidemiology
-
Breast Neoplasms / prevention & control*
-
Catalytic Domain* / drug effects
-
Chemoprevention / methods
-
Drug Discovery*
-
Female
-
Humans
-
Parity / physiology
-
Peptide Fragments / chemical synthesis
-
Peptide Fragments / chemistry
-
Peptide Fragments / therapeutic use
-
Pregnancy
-
alpha-Fetoproteins / chemistry*
Substances
-
Antineoplastic Agents
-
Peptide Fragments
-
alpha-Fetoproteins